A previous regulatory setback in the US for Kissei Pharmaceutical Co., Ltd’s female health product linzagolix has not discouraged the Japanese firm from continued development of the oral gonadotropin-releasing hormone (GnRH) antagonist and building its global presence through new alliances.
Japan Phase III Wins, Asian Alliances Buoy Kissei's Linzagolix
US Refiling Planned
While its European licensee is preparing for an imminent launch, Kissei has also been expanding its partnerships in Asia for female health product linzagolix. A new alliance is also being sought in the US to assist with a new trial and NDA refiling there.
More from Women's Health
• By
Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.